March Quarter Update & Positive FY26 Guidance

• Strong finish to FY26 forecast with best Q4 result since transformation
• Significant earnings improvement with FY26 EBITDA loss narrowing 68-76%
• Growth drivers include Sanofi preferred vendor status and US policy shifts

IDT Australia (ASX:IDT) is pleased to provide a Q3-FY26 update, with the company positioned to deliver a significantly improved full year result. Although Q3 revenue was impacted by seasonal factors, IDT expects its best performing Q4-FY26 since the start of its transformation program. FY26 EBITDA losses are forecast to narrow to $1.5M-$2M, an improvement of 68%-76% on FY25, driven by the evolution of its business model. IDT has been designated a Preferred Vendor by Sanofi following a successful working relationship, providing potential access to other Sanofi global business. Recent US policy developments on psychedelics and medicinal marijuana are also expected to bolster IDT's API and Specialty Orals verticals. The recommissioning of major mothballed facilities is starting to realize financial benefits, enhancing IDT's competitiveness and ability to capture higher-margin work. A new strategic partnership with Fierce Pharma will also accelerate IDT's business development efforts in global pharmaceutical and biotech markets.

IDT is forecasting FY26 operating revenue from its three verticals to increase to between $15 million and $16 million (+4% to +11%), while EBITDA losses are expected to narrow to between $1.5 million and $2 million (vs. FY25 EBITDA loss of $6.3 million).

IDT expects further growth in the year ahead, supported by its Sanofi preferred vendor status, positive US policy changes, recommissioned facilities, and a new strategic partnership with Fierce Pharma to expand its global reach.